IL297240A - Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof - Google Patents
Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereofInfo
- Publication number
- IL297240A IL297240A IL297240A IL29724022A IL297240A IL 297240 A IL297240 A IL 297240A IL 297240 A IL297240 A IL 297240A IL 29724022 A IL29724022 A IL 29724022A IL 297240 A IL297240 A IL 297240A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- lazertinib
- tablet
- mesylate
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US202063014277P | 2020-04-23 | 2020-04-23 | |
| PCT/IB2021/053035 WO2021209893A1 (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297240A true IL297240A (en) | 2022-12-01 |
Family
ID=75562794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297240A IL297240A (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12138351B2 (enExample) |
| EP (1) | EP4135669A1 (enExample) |
| JP (2) | JP7787824B2 (enExample) |
| KR (1) | KR20230002656A (enExample) |
| CN (1) | CN115484937A (enExample) |
| AU (2) | AU2021257662B2 (enExample) |
| CA (1) | CA3180184A1 (enExample) |
| IL (1) | IL297240A (enExample) |
| MX (1) | MX2022012898A (enExample) |
| PH (1) | PH12022552454A1 (enExample) |
| TW (1) | TW202207940A (enExample) |
| UY (1) | UY39171A (enExample) |
| WO (1) | WO2021209893A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| US20240270733A1 (en) * | 2021-06-01 | 2024-08-15 | Hangzhou Solipharma Co., Ltd. | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| US6399591B1 (en) | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| WO2008057267A2 (en) * | 2006-10-27 | 2008-05-15 | Fmc Corporation | Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| ES2713330T3 (es) | 2009-12-11 | 2019-05-21 | Sumitomo Dainippon Pharma Co Ltd | Comprimido recubierto en seco que se desintegra oralmente |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| AU2013347962B2 (en) | 2012-11-21 | 2018-10-25 | Janssen Biotech, Inc. | Bispecific EGFR/c-Met antibodies |
| WO2015006752A1 (en) * | 2013-07-12 | 2015-01-15 | The Regents Of The University Of California | Combination therapies for malaria |
| UA120428C2 (uk) | 2013-12-12 | 2019-12-10 | Алміралл, С.А. | Фармацевтичні композиції, які містять диметилфумарат |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| MX2017003181A (es) | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
| TWI808938B (zh) | 2016-04-07 | 2023-07-21 | 美商卡默森屈有限公司 | 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷 |
| MX389966B (es) * | 2017-01-20 | 2025-03-20 | Exelixis Inc | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
| EP3592338A1 (en) * | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MX393995B (es) | 2017-07-28 | 2025-03-24 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina |
| DK3658553T3 (da) | 2017-07-28 | 2022-07-25 | Yuhan Corp | Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf |
| CN111295381A (zh) | 2017-07-28 | 2020-06-16 | 株式会社柳韩洋行 | 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法 |
| CN110580014B (zh) * | 2018-06-11 | 2021-03-30 | 北京京东尚科信息技术有限公司 | 用于控制自动导引运输车的方法、装置和系统 |
| WO2020018928A1 (en) | 2018-07-20 | 2020-01-23 | Imerys Usa, Inc. | Recovering sand, bentonite and organics from foundry sand waste |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| SG11202110585SA (en) | 2019-04-11 | 2021-10-28 | Goldfinch Bio Inc | Spray-dried formulation of a pyridazinone trpc5 inhibitor |
| EP4268815A3 (en) | 2019-04-17 | 2024-02-21 | NordicCan A/S | Fast disintegrating cannabinoid tablets |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| CA3144840A1 (en) | 2019-07-31 | 2021-02-04 | Leonie Flurina Claude Wagner-Hattler | New pharmaceutical formulation |
-
2021
- 2021-04-12 TW TW110113031A patent/TW202207940A/zh unknown
- 2021-04-13 PH PH1/2022/552454A patent/PH12022552454A1/en unknown
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Pending
- 2021-04-13 US US17/228,753 patent/US12138351B2/en active Active
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
- 2021-04-13 JP JP2022562451A patent/JP7787824B2/ja active Active
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en not_active Ceased
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 AU AU2021257662A patent/AU2021257662B2/en active Active
-
2024
- 2024-11-07 US US18/939,761 patent/US20250177311A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203347A patent/AU2025203347A1/en active Pending
- 2025-08-22 JP JP2025138920A patent/JP2025179094A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021209893A1 (en) | 2021-10-21 |
| PH12022552454A1 (en) | 2024-02-05 |
| US20250177311A1 (en) | 2025-06-05 |
| CA3180184A1 (en) | 2021-10-21 |
| AU2021257662A1 (en) | 2022-12-15 |
| EP4135669A1 (en) | 2023-02-22 |
| US12138351B2 (en) | 2024-11-12 |
| JP7787824B2 (ja) | 2025-12-17 |
| AU2021257662B2 (en) | 2025-06-12 |
| CN115484937A (zh) | 2022-12-16 |
| WO2021209893A8 (en) | 2022-10-13 |
| KR20230002656A (ko) | 2023-01-05 |
| AU2025203347A1 (en) | 2025-05-29 |
| MX2022012898A (es) | 2023-01-24 |
| TW202207940A (zh) | 2022-03-01 |
| JP2023522634A (ja) | 2023-05-31 |
| US20210322323A1 (en) | 2021-10-21 |
| UY39171A (es) | 2021-10-29 |
| BR112022020609A2 (pt) | 2022-11-29 |
| JP2025179094A (ja) | 2025-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297240A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | |
| KR100440553B1 (ko) | 서방성 제제 | |
| IL282163B1 (en) | A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or a salt thereof | |
| NZ583269A (en) | Novel forms of cddo methyl ester also known as methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28 oate | |
| RU2322970C2 (ru) | Фармацевтические композиции, включающие коллоидную двуокись кремния | |
| IL305435A (en) | Psilocybin compositions, methods of making and methods of using the same | |
| IL296014A (en) | Tablets containing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| IL261745B2 (en) | Granular formulation of 5-methyl-1-phenyl-2(h1)-pyridone and method for its preparation | |
| IL293821A (en) | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide | |
| IL224189A (en) | C-met modulator pharmaceutical compositions | |
| IL259493A (en) | Solid dispersions containing sgc actuator | |
| IL298525A (en) | Pralsetinib pharmaceutical compositions | |
| IL303352B1 (en) | Immediate-release tablets containing a drug and processes for forming the tablets | |
| IL297642A (en) | Methods for using t-type calcium channel modulators | |
| IL294959A (en) | Methods of treatment for alpha-1 antitrypsin deficiency | |
| IL296352A (en) | Method for treatment of covid-19-associated conditions | |
| IL297840A (en) | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators | |
| IL298872A (en) | Acalabrutinib maleate dosage forms | |
| IL322310A (en) | Methods for treating multiple sclerosis complex | |
| EA048109B1 (ru) | Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его фармацевтически приемлемую соль, гидрат или сольват | |
| BR112022020609B1 (pt) | Composição e formulação farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo e seus usos | |
| HK40085907A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | |
| IL295992A (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine | |
| HK40105586A (zh) | 包含依那格列净的药物组合物 | |
| KR20240024419A (ko) | 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제 |